We are Sorry, This Page doesn't Exist

Thinly traded nano-cap biotech Cytori Therapeutics Inc (NASDAQ: CYTX), which has been trading in penny stock territory for about a year now, could see some activity in the wake of a company announcement Friday.  read more.....»»

Roche (RHHBY) announced that its immuno-oncology drug, Tecentriq, was recommended for approval by.....»»

Calithera Biosciences Inc (NASDAQ: CALA) shares were making a strong upward move Monday  following a clinical trial readout from the company. read more.....»»

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) read more.....»»

AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

New drugs that trigger a patient’s immune system to kill malignant cells can greatly improve the survival rate of people with the most common type of lung cancer, a new study found. The study, published in the New England Journal of Medicine, found.....»»

Combining expensive cancer immunotherapies with each other or with older drugs prolonged survival in lung cancer patients, two studies show. But the costs are high......»»

Brainstorm Health Daily: April 16, 2018 Hello and happy Monday, readers! This is Sy. New study results released Monday continue to cement drug giant Merck’s status as the force to be r.....»»

In a fierce rivalry to prove cancer drug combinations work better for advanced.....»»

Merck gained.....»»

(Reuters) - Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market......»»

(Reuters) - Merck & Co said on Monday a late-stage trial of its blockbuster cancer drug Keytruda met the main goal in helping previously untreated lung cancer patients live longer, sending its shares up 2.6 percent in premarket trade......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Treating breast-cancer patients with an expensive Roche drug for six months instead of 12 reduced heart-related side effects without sacrificing effectiveness, a new study found......»»

Using Imfinzi in stage III lung cancer, where cancer has only spread locally, opens up a multibillion-dollar sales opportunity.....»»

Roche's (RHHBY) Tecentriq meets its co-primary endpoints of overall survival and progression-free survival in a phase III study for lung cancer. Roche RHHBY announced that the phase III study, IMpower130 on immunot.....»»

Roche Won"t Go Down Without A Fight In The Front-Line Lung Cancer Space.....»»

Pfizer's (PFE) lung cancer drug, Xalkori (crizotinib), gets Breakthrough Therapy designation by the FDA for two new indications. Pfi.....»»

KDALLung Cancer Drug From Merck Solidifies Lead in Crowded FieldBloombergIn the race to.....»»